Abstract:The potential of Reinforcement Learning (RL) has been demonstrated through successful applications to games such as Go and Atari. However, while it is straightforward to evaluate the performance of an RL algorithm in a game setting by simply using it to play the game, evaluation is a major challenge in clinical settings where it could be unsafe to follow RL policies in practice. Thus, understanding sensitivity of RL policies to the host of decisions made during implementation is an important step toward building the type of trust in RL required for eventual clinical uptake. In this work, we perform a sensitivity analysis on a state-of-the-art RL algorithm (Dueling Double Deep Q-Networks)applied to hemodynamic stabilization treatment strategies for septic patients in the ICU. We consider sensitivity of learned policies to input features, time discretization, reward function, and random seeds. We find that varying these settings can significantly impact learned policies, which suggests a need for caution when interpreting RL agent output.
Abstract:Precision oncology, the genetic sequencing of tumors to identify druggable targets, has emerged as the standard of care in the treatment of many cancers. Nonetheless, due to the pace of therapy development and variability in patient information, designing effective protocols for individual treatment assignment in a sample-efficient way remains a major challenge. One promising approach to this problem is to frame precision oncology treatment as a contextual bandit problem and to apply sequential decision-making algorithms designed to minimize regret in this setting. However, a clear prerequisite for considering this methodology in high-stakes clinical decisions is careful benchmarking to understand realistic costs and benefits. Here, we propose a benchmark dataset to evaluate contextual bandit algorithms based on real in vitro drug response of approximately 900 cancer cell lines. Specifically, we curated a dataset of complete treatment responses for a subset of 7 treatments from prior in vitro studies. This allows us to compute the regret of proposed decision policies using biologically plausible counterfactuals. We ran a suite of Bayesian bandit algorithms on our benchmark, and found that the methods accumulate less regret over a sequence of treatment assignment tasks than a rule-based baseline derived from current clinical practice. This effect was more pronounced when genomic information was included as context. We expect this work to be a starting point for evaluation of both the unique structural requirements and ethical implications for real-world testing of bandit based clinical decision support.